Neurodegenerative disorders are due to excessive neuronal apoptosis and the caspase-3 plays a key role in the apoptotic pathway. The caspase-3 inhibition may be a validated therapeutic approach for neurodegenerative disorders and an interesting target for molecular modeling studies using both Ligand and structure based approaches. In view of the above we have generated the Ligand based pharmacophore model using the Discovery studio 2.0 software. In addition to this a structure based approach has been used to validate the developed pharmacophoric features to gain a deeper insight into its molecular recognition process. This validated pharmacophore and the docking model was then implemented as a query for pharmacophore based virtual screening to prioritize the probable hits for the Caspase-3. Two ligands, ZINC12405015 and ZINC12405043 were finally selected on the basis of their fit values and docking scores. This study also reveals the important amino acids viz. His-121, Ser-205, Arg-207 which were found to be playing crucial role in the binding of the selected compounds within the active site of caspase-3.

Download full-text PDF

Source
http://dx.doi.org/10.2174/1871527313666141023120843DOI Listing

Publication Analysis

Top Keywords

neurodegenerative disorders
8
structure based
8
caspase-3
5
identification potent
4
potent caspase-3
4
caspase-3 inhibitors
4
inhibitors treatment
4
treatment multi-
4
multi- neurodegenerative
4
neurodegenerative diseases
4

Similar Publications

Importance: Sporadic Creutzfeldt-Jakob disease (sCJD) is a rare, rapidly progressive and fatal neurodegenerative disease. Definite sCJD diagnosis can only be made post mortem, and little is known about the prodromal phase of the disease.

Objective: To compare drug prescription patterns before the clinical onset of sCJD between patients and matched controls for exploration of potential risk factors and to assess correlations between drug exposure and sCJD survival.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Department of Neurology & Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, National Center for Neurological Disorders, Beijing, Beijing, China.

Background: It is challenging to distinguish which subcortical ischemic vascular disease (SIVD) patients will present with cognitive impairment. A blood-based biomarker to distinguish SIVD patients with cognitive impairment would be superior to neuropsychological measures and neuroimaging measures in terms of cost, time, and feasibility for repeated measures. Metabolomics profiling studies could help identify blood-based biomarkers for SIVD patients with cognitive impairment.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

UT Health San Antonio, San Antonio, TX, USA.

Background: The Amyloid-Tau-Neurodegeneration (ATN) biomarker framework for Alzheimer's disease (AD) indicates binary (presence/absence) designations for each type of pathology, without regard for anatomical distribution. Neurodegeneration is designated as positive if atrophy or hypometabolism are found on imaging. However, Clifford Jack et al.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

NYU Grossman School of Medicine, New York, NY, USA.

Background: The choroid plexus (ChP) plays a vital role in CSF production and waste clearance. While existing imaging studies have established connections between ChP volume changes and age-related neurodegenerative diseases, a comprehensive investigation into the microstructural and vascular changes associated with aging remains insufficient. This study aims to explore ChP changes in normal aging using diffusion and perfusion MRI in the HCP-Aging dataset to enhance our understanding of age-related microstructural and vascular changes in the ChP.

View Article and Find Full Text PDF

Background: This research introduces a novel method for quantifying aggregated tau in body fluids, specifically cerebrospinal fluid (CSF), aiming to enhance the diagnosis and monitoring of neurodegenerative diseases, with a focus on Alzheimer's disease (AD).

Method: By combining tau protein amplification with a highly sensitive single-molecule array (Simoa) immunoassay using an anti-tau antibody CT19.1 in a homogenous manner, the approach enables precise measurements of tau aggregates in CSF.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!